GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: PL37 is an investigational, orally available, dual pro-drug inhibitor of neprilysin (a.k.a. neutral endopeptidase or NEP; MME) and aminopeptidase N (APN; ANPEP) [3]. NEP and APN are enkephalin catabolising enzymes (or enkephalinases). Dual ENKephalinase inhibitors such as this one have been ascribed the acronym DENK inhibitor (or DENKi). PL37 is the non-stereo enantiomer of compound 15 in patent US8247609 [4]. Such dual inhibitors are suggested as a novel mechanism for the control of central and peripheral pain [5], via inhibition of enzymatic degradation of endogenous enkephalins. Such agents could replace the use of opiate analgesics. | 
 | |||||||||||||||||||||||||||||||||||
| No information available. | 
| Summary of Clinical Use  | 
| A Phase 2a trial of PL37 in patients with peripheral neuropathic pain of diabetic origin is underway in France and the UK (EudraCT Number: 2013-004876-37). |